COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI BUBU BHBH BLBL CICI HC QHC Q NZNZ COCO More..
00.250.50.7511.251.51.752+Ashraf (RCT)82%0.18 [0.04-0.80]death2/15711/156CT​1Improvement, RR [CI]TreatmentControlAl-Haidari (RCT)96%0.04 [0.00-0.70]death0/16014/259Koshak (RCT)75%0.25 [0.03-2.22]hosp.1/914/92Tau​2 = 0.00; I​2 = 0.0%Early treatment84%0.16 [0.05-0.48]3/40829/50784% improvementAll studies84%0.16 [0.05-0.48]3/40829/50784% improvement3 nigella sativa COVID-19 studiesc19ns.com Aug 29, 20211 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 3.23Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Ashraf (RCT)82%0.18 [0.04-0.80]2/15711/156CT​1Improvement, RR [CI]TreatmentControlAl-Haidari (RCT)96%0.04 [0.00-0.70]0/16014/259Tau​2 = 0.00; I​2 = 0.0%Early treatment87%0.13 [0.04-0.49]2/31725/41587% improvementAll studies87%0.13 [0.04-0.49]2/31725/41587% improvement2 nigella sativa COVID-19 mortality resultsc19ns.com Aug 29, 20211 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 3.02Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Koshak (RCT)75%0.25 [0.03-2.22]hosp.1/914/92Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment75%0.25 [0.03-2.22]1/914/9275% improvementAll studies75%0.25 [0.03-2.22]1/914/9275% improvement1 nigella sativa COVID-19 hospitalization resultc19ns.com Aug 29, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 1.24Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Ashraf (RCT)82%0.18 [0.04-0.80]death2/15711/156CT​1Improvement, RR [CI]TreatmentControlAl-Haidari (RCT)96%0.04 [0.00-0.70]death0/16014/259Koshak (RCT)75%0.25 [0.03-2.22]hosp.1/914/92Tau​2 = 0.00; I​2 = 0.0%Early treatment84%0.16 [0.05-0.48]3/40829/50784% improvementAll studies84%0.16 [0.05-0.48]3/40829/50784% improvement3 nigella sativa COVID-19 serious outcomesc19ns.com Aug 29, 20211 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 3.23Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Ashraf (RCT)82%0.18 [0.12-0.27]107 (n)103 (n)CT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment82%0.18 [0.12-0.27]0/1070/10382% improvementAll studies82%0.18 [0.12-0.27]0/1070/10382% improvement1 nigella sativa COVID-19 viral clearance resultc19ns.com Aug 29, 20211 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 8.68Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Ashraf (RCT)82%0.18 [0.04-0.80]death2/15711/156CT​1Improvement, RR [CI]TreatmentControlAl-Haidari (RCT)96%0.04 [0.00-0.70]death0/16014/259Koshak (RCT)75%0.25 [0.03-2.22]hosp.1/914/92Tau​2 = 0.00; I​2 = 0.0%Early treatment84%0.16 [0.05-0.48]3/40829/50784% improvementAll studies84%0.16 [0.05-0.48]3/40829/50784% improvement3 nigella sativa COVID-19 Randomized Controlled Trialsc19ns.com Aug 29, 20211 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 3.23Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Ashraf (RCT)82%0.18 [0.04-0.80]2/15711/156CT​1Improvement, RR [CI]TreatmentControlAl-Haidari (RCT)96%0.04 [0.00-0.70]0/16014/259Tau​2 = 0.00; I​2 = 0.0%Early treatment87%0.13 [0.04-0.49]2/31725/41587% improvementAll studies87%0.13 [0.04-0.49]2/31725/41587% improvement2 nigella sativa COVID-19 RCT mortality resultsc19ns.com Aug 29, 20211 CT: study uses combined treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 3.02Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Al-Haidari (RCT)96%0.04 [0.00-0.70]death0/16014/259Improvement, RR [CI]TreatmentControlKoshak (RCT)75%0.25 [0.03-2.22]hosp.1/914/92Tau​2 = 0.00; I​2 = 0.0%Early treatment87%0.13 [0.02-0.72]1/25118/35187% improvementAll studies87%0.13 [0.02-0.72]1/25118/35187% improvement2 nigella sativa COVID-19 peer reviewed trialsc19ns.com Aug 29, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 2.33Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Ashraf (RCT)82%0.18 [0.04-0.80]death2/15711/156CT​1Improvement, RR [CI]TreatmentControlAshraf (RCT)67%0.33 [0.01-7.99]death0/1071/103CT​1Ashraf (RCT)79%0.21 [0.05-0.92]death2/5010/53CT​1Ashraf (RCT)84%0.16 [0.11-0.24]no recov.107 (n)103 (n)CT​1Ashraf (RCT)75%0.25 [0.15-0.41]no recov.50 (n)53 (n)CT​1Ashraf (RCT)82%0.18 [0.12-0.27]viral+107 (n)103 (n)CT​1Ashraf (RCT)77%0.23 [0.14-0.38]viral+50 (n)53 (n)CT​1Al-Haidari (RCT)96%0.04 [0.00-0.70]death0/16014/259Al-Haidari (RCT)93%0.07 [0.02-0.30]severe case2/16044/259Koshak (RCT)75%0.25 [0.03-2.22]hosp.1/914/92Koshak (RCT)43%0.57 [0.42-0.78]no recov.34/9160/92nigella sativa COVID-19 outcomesc19ns.com Aug 29, 2021Lower RiskIncreased Risk
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home